It's time to halt product security decline

Companies investing now to build high-efficiency, high-visibility, strong supply and distribution networks are the ones that will be winning over the next few years. That's the conclusion of this year's Pharmaceutical Commerce Product Security Supplement.

Yet despite that conclusion, and despite new technologies and progress on standards and regulations, pharmaceutical product security is on a three-year decline. California's decision in 2008 to postpone until 2015 its e-pedigree mandate put the brakes on technology and process solutions in the making that for the most part have yet to be revived.

The pharma industry is largely maintaining its reactive status quo of hiring investigators to locate counterfeiters, documenting cargo thefts and monitoring rogue websites.

"A saner policy should be to build a stronger, better defended supply chain that prevents diversion and counterfeiting from entering the picture," writes editor Nick Basta. "But that seems to be a leap the industry is taking painfully slowly, absent a regulatory goad."

- see the article

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.